Healthcare Industry News: Dysport
News Release - January 11, 2016
Galderma Laboratories, L.P. Appoints Miles Harrison as Leader of U.S. and CanadaFORT WORTH, Texas, Jan. 11, 2016 -- (Healthcare Sales & Marketing Network) -- Galderma, a global leader focused on medical solutions in dermatology and skin health, has announced today the promotion of Miles Harrison to President and General Manager of Galderma Laboratories, L.P. leading the U.S. and Canada teams.
Miles Harrison joined Galderma U.S. in 2014 as the Vice President and General Manager of the company's Self-Medication Business Unit, which includes Galderma's flagship brand Cetaphil®. Under his leadership, the Self-Medication Business Unit has grown significantly and launched several new over-the-counter brands including Benzac® Acne Solutions, a full line of acne treatment products; Excipial™ Skin Solutions, a new therapeutic skincare line engineered for challenged skin; Qilib™ Hair Regrowth + Revitalization System, with lines for men and women; and Cetaphil® Men and Cetaphil® Baby lines.
"Galderma is experiencing a tremendous amount of growth following the launch of eight new products across all three business units in the U.S. over the past 18 months," said Stuart Raetzman, Chief Executive Officer of Galderma Pharma S.A. "Miles has the vision and experience to lead our organization at this exciting time of rapid and sustainable growth."
The North America affiliate has recently aligned its structure to Galderma's global strategy, re-organizing into three business units to accommodate new product launches and acquisitions. In addition to the Self-Medication Business Unit, the Prescription Business Unit includes the most-prescribed topical brand of acne treatment in the world, Epiduo® Gel, and Epiduo® Forte Gel, as well as prescription medications for rosacea such as Soolantra® Cream and Oracea® Capsules and more. The Aesthetic and Corrective Business Unit comprises a broad portfolio including Restylane® Silk, Restylane® Lyft, Dysport® and Sculptra® Aesthetic. To support this growth, in fall 2015, the company announced the addition of a 100,000 square-foot, $22 million research, development and training building to its current 170,000 square-foot headquarters. This expansion is anticipated to add as many as 350 employees to the current 300 in Fort Worth.
"I am honored to take this leadership position at a time when Galderma is experiencing such fantastic growth and transformation," said Miles Harrison. "I am proud to be part of a company consistently trusted by doctors and patients that is truly changing people's lives with its solutions for skin health. We are committed to meeting the dermatological needs of people throughout their lives and we will continue to deliver innovative medical solutions to healthcare professionals, patients and consumers."
Miles Harrison brings a substantial amount of prescription, consumer and business experience throughout his 20 year career to this leadership position. Prior to joining Galderma, he held numerous vice president positions at Novartis. He is a British national and has worked and lived in several countries, including the U.S., U.K., Switzerland, Saudi Arabia, Poland and Latin America. Harrison holds a Bachelor of Arts degree from Sheffield Hallam University in the United Kingdom.
Dating back to 1961, Galderma is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.
Strategic brands in the U.S. include Epiduo® Gel, Epiduo® Forte Gel, Oracea® Capsules, Clobex® Spray, Differin® Gel, Mirvaso® Gel, MetroGel® Gel, Soolantra® Cream, Vectical® Cream, Tri-Luma® Cream, Cetaphil®, Benzac® Acne Solutions, Excipial™ Skin Solutions, Qilib™, Restylane®, Restylane® Silk, Restylane® Lyft, Dysport® (abobotulinumtoxinA) and Sculptra® Aesthetic.
For more information, please visit www.galdermausa.com and www.galderma.com
All trademarks are the property of their respective owners.
Source: Galderma Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.